SCHEMBL1103670

SCHEMBL1103670

c1ccc(-c2ccc(-c3ccc4c(-c5ccc6ccccc6c5)c5cnccc5c(-c5cccc6ccccc56)c4c3)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.47
CYP17A1 P05093 1/20 0.45
CYP19A1 P11511 1/20 0.45
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
MAPK10 P53779 4/20 0.41
CCNC P24863 2/20 0.37
CDK8 P49336 2/20 0.37
TDO2 P48775 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PIM1 P11309 1/20 0.37
SIRT2 Q8IXJ6 3/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103664 1.00 TNF (0.47) TNFCYP17A1CYP19A1CYP11B1CYP11B2
SCHEMBL1103694 0.99 TNF (0.46) TNFCYP17A1CYP19A1CYP11B1CYP11B2
SCHEMBL1103671 0.96 CYP11B1 (0.44) TNFCYP17A1CYP19A1CYP11B1CYP11B2
SCHEMBL1102972 0.95 TNF (0.51) TNFCYP17A1CYP19A1CYP11B1CYP11B2
SCHEMBL1103632 0.94 CYP11B1 (0.47) TNFCYP17A1CYP19A1CYP11B1CYP11B2
SCHEMBL1103668 0.93 TNF (0.50) TNFCYP17A1CYP19A1CYP11B1CYP11B2
SCHEMBL1103667 0.93 TNF (0.46) TNFCYP17A1CYP19A1CYP11B1CYP11B2
SCHEMBL1102784 0.93 CYP11B1 (0.49) TNFCYP17A1CYP19A1CYP11B1CYP11B2
SCHEMBL1102816 0.93 CYP11B1 (0.48) TNFCYP17A1CYP19A1CYP11B1CYP11B2
SCHEMBL1103621 0.93 TNF (0.54) TNFCYP17A1CYP19A1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 TNF 3803/4885CYP17A1 2034/4885CYP19A1 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.